The drug is the first to be approved in Japan to treat children and adolescents with generalised myasthenia gravis

The drug is currently being assessed in a phase 1b/2a clinical trial

Updated Date: Wed, 16 Aug 2023 00:00:00 EDT

Updated Date: Wed, 16 Aug 2023 00:00:00 EDT

Updated Date: Wed, 16 Aug 2023 00:00:00 EDT

Updated Date: Wed, 16 Aug 2023 00:00:00 EDT

Updated Date: Wed, 16 Aug 2023 00:00:00 EDT

Myrian describes the challenges she faces engaging in healthcare consultations after an acquired brain injury.1Her brain injury is […]

Launer describes the devastating effects of nuclear weapons and highlights the moral responsibility of medical professionals to prioritise […]

The varicella zoster virus that causes shingles and chicken pox is typically present in over 90% of adults […]